Understand the source comparison
Follistatin-344 for Body Composition: Research Models Comparison
The table below compares key research models examining Follistatin-344 for body composition outcomes, organized by intervention type, observed effects, and methodological considerations. Myostatin Knockout (Genetic) Complete myostatin gene deletion 200–300% in
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares key research models examining Follistatin-344 for body composition outcomes, organized by intervention type, observed effects, and methodological considerations.
- Myostatin Knockout (Genetic)
- Complete myostatin gene deletion
- 200–300% increase in muscle mass; 25–35% reduction in fat mass
- Improved glucose tolerance; reduced circulating triglycerides; increased basal metabolic rate
- Phenotype present at birth; maximum effect by 12 weeks postnatal
- Gold standard for proof-of-concept but not pharmacologically achievable. Useful for mechanism validation only
- AAV-Follistatin Gene Therapy
- Single intramuscular injection of adeno-associated virus encoding Follistatin-344
- 15–30% increase in treated muscle group cross-sectional area; localized fat reduction in adjacent adipose tissue
- Insulin sensitivity improvement in treated limb; no systemic glucose effects observed
- Hypertrophy detectable by week 4; peak effect at 12–16 weeks
- High efficacy but limited to localized tissue. Not suitable for whole-body composition studies; used primarily in muscular dystrophy research
- Recombinant Follistatin-344 Subcutaneous
- Biweekly subcutaneous injection at 100–500 mcg/kg
- 8–15% increase in total lean mass; 10–18% reduction in body fat percentage
- Elevated serum IGF-1 (15–25% above baseline); improved insulin sensitivity; reduced fasting glucose
- Lean mass changes detectable by week 6; fat reduction by week 8–10
- Most translationally relevant model for body composition research. Systemic delivery, dose-dependent response, reversible upon cessation
- Myostatin Antibody (Monoclonal)
- Biweekly injection of myostatin-neutralizing antibody
- 12–20% increase in lean mass; minimal fat reduction (3–8%)
- Modest IGF-1 elevation; no consistent glucose or lipid changes
- Lean mass detectable by week 8; slower onset than Follistatin-344
- Mechanism overlaps with Follistatin-344 but lacks additional activin-binding activity. Less pronounced body composition shift
- Follistatin-344 + Exercise Training
- Subcutaneous Follistatin-344 + resistance exercise protocol
- 25–40% increase in trained muscle cross-sectional area; 20–28% fat reduction
- Synergistic insulin sensitivity improvement; enhanced mitochondrial biogenesis markers
- Hypertrophy detectable by week 3–4; compounding effect through week 12
- Demonstrates additive effect of myostatin inhibition + mechanical load. Closest model to human performance enhancement research
- Recombinant Follistatin-344 subcutaneous administration is the most widely adopted model in current body composition research because it mirrors clinically translatable pharmacology. Defined dosing intervals, systemic distribution, and reversible effects. The combination model (Follistatin-344 + exercise) is particularly valuable for laboratories studying performance enhancement, sarcopenia reversal, or metabolic disease interventions where both pharmacological and lifestyle factors interact.